---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-041186"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T14:03:55.415940+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Olema reports FY2024 net loss $129.5M; cash $434.1M; palazestrant Phase 3 on track

## Summary
- Net loss Q4 $33.6M, FY $129.5M vs. $26.8M and $96.7M in 2023; R&D expense $124.5M FY.
- Cash, equivalents & marketable securities $434.1M at Dec 31, 2024, up from $250M private placement.
- Phase 3 OPERA-01 monotherapy top-line data expected 2026; OPERA-02 combo trial with Novartis starts 2025.
- Phase 1 trial of OP-3136 initiated in Q4 2024; patients currently enrolling.
- Updated mPFS data for palazestrant + ribociclib presented at March 2025 TD Cowen; mature data pending.

## SEC filing metadata
- accession: 0000950170-25-041186
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017025041186/0000950170-25-041186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017025041186/olma-20250318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-041186
- JSON: https://secwatch.observer/filing/0000950170-25-041186.json
- Plain text: https://secwatch.observer/filing/0000950170-25-041186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.